Category Archives: Regenerative Medicine

Liver is the second largest and one of the most complex organs in the body, yet awareness regarding liver diseases continues to be low. This is why, World Liver Day is observed on April 19 every year to create awareness about diseases related to the liver. Dr Prashant Vilas Bhangui, associate director, Institute of Liver Transplantation and Regenerative Medicine, Medanta Hospital, Gurugram answers some frequently asked questions related to liver diseases.

What is cirrhosis of the liver?

Liver disease initially starts off with fatty liver (where there is an accumulation of excess fat in the liver). This then progresses to fibrosis of the liver which leads to stiffness, and ultimately end-stage liver disease or cirrhosis, the expert added.

Causes

The most common causes of liver disease are viral hepatitis i.e., hepatitis C and hepatitis E, excessive consumption of alcohol, and an unhealthy lifestyle that may cause obesity. A patient who drinks alcohol for prolonged periods of time in substantial quantity ultimately develops cirrhosis. Additionally, people who are overweight, lead an unhealthy lifestyle, have unhealthy diet, lack physical activity, and suffer from co-morbid conditions like diabetes, hypertension, thyroid disorders, and abnormal cholesterol levels are at a risk of developing non-alcoholic fatty liver disease (NAFLD), which progresses to cirrhosis. NAFLD has become a leading cause of cirrhosis of the liver in many countries. Other congenital causes of cirrhosis in children are biliary atresia, metabolic disease of the liver. Some rare causes include autoimmune hepatitis, Wilsons disease, and hemochromatosis.

Symptoms

Initially, a patient may experience constant lethargy, fatigability, swelling of the feet after walking, jaundice, fluid in the abdomen, episodes of bleeding, portal hypertension in the later stage leading to vomiting of blood, blood in stools, internal bleeding. Liver failure also affects other organs like kidney, and even leads to memory loss, and drowsiness.

Diagnosis

If someone has a genetic pre-disposition to cirrhosis and has symptoms of liver disease or is suffering from viral hepatitis for a long period of time, they must get some blood tests, liver function tests, abdominal ultrasound, CT scan, and endoscopy done to understand the stage of cirrhosis they are at.

Stages

Compensated cirrhosis The liver functions get damaged to a great extent; however, the body somehow copes with that liver function, sometimes to an extent of 50-60 per cent.

Decompensated cirrhosis When the liver damage becomes more than about 70-80 per cent. The patients gets symptoms like swelling of the feet, accumulation of fluids in the abdomen, bleeding tendencies, and effects on other organs e.g., on kidneys and brain.

Can cirrhosis be cured?

Once the liver reaches the stage of cirrhosis, the disease becomes irreversible. Fatty liver and early stage of liver fibrosis can be cured through medications along with diet control, understanding causes, and taking proper actions to reverse the condition. Patients at the stage of cirrhosis are highly recommended medical therapies, to support the liver and prevent the progression of the disease. The doctor, based on the CTP (Child-Turcotte-Pugh) score, and other additional scores, determines the treatment procedure i.e., medical treatment or to undergo liver transplantation.

Prevention tips

There are some high-risk individuals who may get exposed to hepatitis B and C like healthcare workers, and patients having blood transfusions, hould be extra vigilant and take extra precautions. The viral markers used to identify a range of Hepatitis B, C, and other viral infections needed to be checked at regular intervals. Experts suggest undergoing an annual check-up including a liver function test, and an ultrasound after the age of 45-50, blood tests are done for early detection, especially for the people who are diabetic, hypertensive, and have thyroid disorders.

People should avoid excessive consumption of alcohol, have a healthy diet, avoid fried and junk food, exercise regularly, avoiding smoking, etc.

Is it possible to cleanse the liver? Is it a myth?

Its more of a myth than reality. There is nothing called cleansing a liver. One can take effective measures including liver-friendly juices, staying hydrated, and eating healthy foods that help in maintaining the healthy liver.

For more lifestyle news, follow us on Instagram | Twitter | Facebook and dont miss out on the latest updates!

Original post:
World Liver Day 2022: Expert answers frequently asked questions - The Indian Express

Pediatric immunologist Louise Markert, MD, PhD, spent 30 years working to develop a viable treatment to save children born with congenital athymia, a group of rare diseases such as complete DiGeorge Syndrome that are characterized by the lack of a functioning thymus. Without the gland, which trains the bodys T-cells to fight pathogens, minor infections can be fatal; untreated children with congenital athymia typically die by the age of three.

On October 8, 2021, Markert's long journey came to fruition whenthe U.S. Food and Drug Administration (FDA) approved a regenerative medicine based on her pioneering work as the only therapy for congenital athymia.The therapy, licensed to Ezyvant Therapeutics, uses cultured thymus tissue to generate a functioning immune system in children without a thymus. In clinical trials, children who received the treatment showed dramatically improved survival rates. FDA approval makes the new therapy available beyond clinical study.

"This really has been the culmination of my career at Duke. It's just overwhelming how happy one can be, helping these children," Markert said.

There's more to come. The foundation set by herresearch is expanding transplant opportunities, as seen by the recent combinationheart/thymus transplant in a baby at Duke that represents a milestone in heart transplantation.

Continued here:
Pioneering Therapy Gives New Hope to Babies Lacking Thymus - Duke Today

STEM cell technology, rivalling that used on humans, is being employed in the treatment of animals by a cutting-edge veterinary practice.

Oakhill Veterinary Practice is attracting interest from pet owners and professionals across Cumbria with its innovative approach to maximising animal welfare.

The practice, based in Windermere, has just taken delivery of its latest high-tech equipment including a Stance Analyser and Regenerative Medicine kit, allowing the practice to now offer platelet-rich plasma (PRP) and stem cell therapy to be used in a variety of conditions.

Regenerative Medicine is an established treatment option in the equine world but is gaining more traction with canine companions.

Principally the anti-inflammatory, regenerative and healing capacity of the animals own cells are harnessed and then employed to treat the dogs orthopaedic or neurological condition.

The equipment can separate stem cells from harvested bone marrow or can be used to concentrate platelets which are then injected into parts of the animals body requiring treatment, such as arthritic joints, tendon and ligament injuries, muscle sprains, acute and chronic soft tissue injuries and certain spinal conditions.

Because the cells come from the animals own body there is minimal risk of rejection or side-effects, according to the practice.

And by using regeneration to heal the tissue, the use of drug therapy can be minimised.

Stem cells are immature cells that dont know what their job as an adult cell will be, said practice partner Alex Kirby.

As they mature, their destiny is dictated by neighbouring tissues in the body, whether that is cartilage, skin, nerve or tendon, essentially allowing those damaged tissues to heal, repair and regrow.

The practice is one of only a handful in the country using these techniques which have been pioneered and refined for use in dogs in America.

The equipment is also used to prepare platelet-rich plasma, which is hugely anti-inflammatory and again stimulates healing. Depending on the condition of an arthritic joint, the beneficial effects can last up to 24 months and means some dogs can live life off most, if not all, medication.

The practice has also invested in a specialised stance analyser which measures the distribution of weight carried through each leg, expressed as a percentage of bodyweight. This allows the vets to pinpoint problem areas at an earlier stage than waiting for the dog to show overt signs of pain.

Vet Marcelle Cassar, clinical director of the Animal Rehabilitation Centre (ARC), said: There are many potential yet subtle orthopaedic issues with dogs; this equipment will help to highlight them for us.

Additionally, it will be instrumental in tracking the progress of the dog as it goes through its rehabilitation programme in the Animal Rehabilitation Centre, for example after orthopaedic surgery.

The idea behind investing in this piece of equipment is to help us measure how well we are progressing with our treatment in a quantifiable way, she said. It gives us hard data and will be used alongside other pain-scoring measures, such as questionnaires, which are more subjective. Our aim is always to improve a dogs comfort and mobility and this will help us to do that.

The new equipment is the latest phase of development in a practice, run by Alex and partner Matthew Stables, that offers end-to-end care, from initial consultation and diagnosis, to surgery, regenerative medicine and rehabilitation including hydrotherapy, physiotherapy, laser treatment, acupuncture and massage therapy.

Oakhill Vet Group also shares its expertise with other vet practices taking referral work in soft-tissue and orthopaedic surgery, rehabilitation and behaviour cases.

Alex, who also sits on the Lakeland Veterinary Association Committee, said: We are trying to get as close to perfect as possible with the management and treatment of a host of degenerative conditions in our pets. This technology is the next bit of the jigsaw and now that it is available to us we can use it to learn what we need to do together to maximise animal care.

Follow this link:
Oakhill Veterinary Practice in Windermere employs groundbreaking technology | The Westmorland Gazette - The Westmorland Gazette

DUBAI, UAE, April 13, 2022 /PRNewswire/ -- European Wellness Biomedical Group (EW Group), through its Malaysian subsidiary European Wellness Academie, and Dubai- based healthcare distribution and technology group, AK International LLC, have signed a Memorandum of Understanding (MOU) on 30th March 2022 that aims to strengthen the medical tourism linkages and access to Biological Regenerative Medicine services in the United Arab Emirates and Malaysia.

EW Group and AK International's MOU signing was the first to be finalised during the signing ceremony, under the witness of Malaysias Prime Minister YAB Datuk Seri Ismail Sabri Yaakob, Science, Technology and Innovation Minister Datuk Seri Dr Adham Baba, International Trade and Industry Minister Datuk Seri Mohamed Azmin Ali, Rural Development Minister Datuk Seri Mahdzir Khalid, and Deputy Minister of Works Datuk Arthur Joseph Kurup.

Logo (PRNewsfoto/European Wellness Biomedical Group)

The signing marks a significant milestone in EW Group's effort to scale up the global adoption of rapidly emerging German and Swiss medical paradigms and cell-based bio- therapeutics for the integrative management of chronic degenerative conditions and untreatable rare diseases.

Witnessed by YAB Dato' Sri Ismail Sabri Yaakob, Prime Minister of Malaysia, the MOU were signed by Prof. Dato' Sri Dr. Mike Chan, European Wellness Group Chairman and Dr. Aasif Ali Siddiqui, Managing Director of AK International.

The strategic collaborations seeks to setup two Centers of Excellence, one specializing in the rehabilitation, education and holistic management of pediatric neurodegenerative and neurodevelopmental disorders such as Autism Spectrum Disorder, Cerebral Palsy, Down Syndrome and Global Developmental Delay, and another specializing in the management of untreatable and rare diseases such as CHARGE Syndrome, Multiple Sclerosis, Rheumatoid Arthritis, Parkinson's Disease etc.

EW Group Chairman Prof. Dato' Sri Dr. Mike said, "We are confident that our 30 years of cell therapeutic research efforts across Europe, along with a passionate team of international top clinicians trained in Germany and Switzerland, can support the delivery of an impactful and personalized disease management model to the communities in UAE."

"Moreover, these Centers are also vital frontlines to assist local patients seeking for biological regenerative medicine solutions at our overseas destinations to have easy access to an efficient and collaborative case referral network from initial inquiry, to preliminary medical investigation, to assisted medical travel, and finally to follow-up care," he said.

Story continues

Since 2017, EW Group has embraced the growth strategies of licensing its proprietary clinical systems, protocols and patented bio-therapeutics to new joint-ventures, rendering the rapid expansion of its healthcare facility division from 2 flagship centers in Switzerland and Malaysia in 2016 to a global network of 26 medical and healthcare centers today.

In addition, EW Group and AK International are looking into the development of a technology driven 'Digital Wellness Service Corridor', in the form of an AI-driven application pioneered by AK International's subsidiary Artelir Inc. that shall seamlessly connect patients from United Arab Emirates with healthcare service providers in Malaysia.

AK International Director Dr. Aasif Ali Siddiqui commented, "One of the goals of this MOU is to increase medical and wellness tourism in Malaysia while also offering Emiratis modern medical treatments in other countries. Patients with incurable uncommon diseases or neurodegenerative disorders, for example, may have restricted access to innovative treatment alternatives, such as cell-based or biomolecular therapies, in their local area."

The partnership is also set to explore potential investments into Iskandar Malaysia Development Area in Johor for the development of a world-leading Halal Hub for Biotechnology and Regenerative Medicine. The unique development project valued at USD 60million shall comprise a 100-bed integrative medicine hospital modelled after EW Group's medical facility in Germany, Muslim-centered aged care retirement villas and assisted living apartments, and a GMP-certified halal biologics and botanical drug manufacturing facility.

"Our Group is ever ready to extend more than 50 of our proprietary plant-based pharmaceuticals with German approval for immediate production in Malaysia and export to meet the growing global demand for natural medicine," Dato' Sri Mike said.

"This project will bring a tremendous opportunity to strengthen Malaysia's vision and current positioning as the world's Muslim hub for innovative biotechnology developments, especially on herbal medicine research and botanical drug manufacturing."

EW Group is a recipient of multiple awards for its pioneering biotech innovations in Paris, Geneva, London and Kuwait, and currently holds multiple international patents on innovative biotechnological processes and formulation for its Cell and Gene Therapy Products (CGTP) and Biologics, including precursor (progenitor) stem cells, biological peptides and anti-idiotypic antiobodies for immunology and botanical formulation for parenteral nutrition.

About European Wellness Biomedical Group

European Wellness Biomedical Group (EW Group) is an award-winning European group founded by Prof. Dato' Sri Dr. Mike Chan and Prof. Dato' Sri Dr. Michelle Wong in early '90s in Switzerland through the culmination of early cell therapeutic research efforts spanning across Switzerland, Germany, Russia and Austria since the mid '80s.

Today, EW Group is most renowned for its pioneering developments in organ-specific precursor (progenitor) stem cell therapeutics, biological and synthetic peptides, biological regenerative medicine, immunotherapies, nutraceuticals and cosmeceuticals. EW Group's multinational business divisions include research and development; bio-manufacturing; biomedical academies for continuing education and training (including 20+ published medical books, 50+ scientific journals and 20+ international accreditations); medical facilities and anti-ageing centres; and nutraceutical product distribution to licensed practitioners and consumers across 80 countries worldwide.

EW Group also owns and operates a growing network of internationally accredited Hospital and Medical Centers specialising in Regenerative Biomedicine and luxury Wellness Centres globally. Currently, the Group is headquartered in Germany and Malaysia (Asia Pacific) with its own research and biopharmaceutical manufacturing facilities vested in Germany, Switzerland, United States, Czech Republic, and United Kingdom.

Home

Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/european-wellness-signs-mou-in-dubai-expo-2020-to-strengthen-medical-tourism-into-malaysia-and-develop-advanced-biological-regenerative-medicine-in-uae-301524937.html

SOURCE European Wellness Biomedical Group

See the original post:
European Wellness Signs MOU in Dubai Expo 2020 to Strengthen Medical Tourism into Malaysia and Develop Advanced Biological Regenerative Medicine in...

QC Kinetix (Doral) began operations in 2022 and operates under the aegis of QC Kinetix Group. The clinic is responding to concerns about expensive chronic pain treatment and the agony of undergoing surgery by introducing the new safe and efficient regenerative medicine. The non-surgical regenerative therapies have been tested and found effective in treating knee pain, back pain, arthritis pain, hip pain, elbow pain, shoulder pain, and joint pain. Another plus is that these non-surgical therapies produce long-lasting results, resulting in improved function and enhanced quality of life. The pain control clinic provides a zero obligation consultation to determine if the treatment is suitable.

Experienced physicians guide patients undergoing natural pain treatments at QC Kinetix (Doral). The treatment protocols targeting injuries and musculoskeletal conditions are carefully orchestrated to allow the body to self-heal and repair. With the new treatment, a lengthy recuperation period is no longer a factor.

At the QC Kinetix (Doral), patients enjoy personalized concierge-level service and treatments that promise long-lasting results. The medical providers include Sander Fernandez M.D., Milton Menco PA-C, Caitlin Sablotsky PA-C. Dr. Sander Fernandez, who is also the Medical Director and board-certified family medicine physician focused on regenerative medicine and non-surgical pain treatment, is passionate about sports medicine and musculoskeletal pain. Milton Menco, a native of Columbia, is a certified physician assistant who has served as a medical laboratory researcher and an expert in the exercise physiology field.

The regenerative medicine Doral utilizes tested and controlled regenerative therapies to achieve treatment goals like reducing inflammation, improving pain experiences, and engineering the natural repair of injured or degenerated tissues. Patients also receive the education they need concerning their conditions and the available treatment options. As a practice, the primary goal is to get patients back on their feet in the shortest time possible. Patients can visit the clinic if they experience body weakness, limited joint mobility, cramping and discomfort, swelling and stiffness, and difficulty completing daily tasks.

The successes of the biologic therapies are documented in video testimonials posted on YouTube and the clinics website. In an account involving a patient with knee pain, the patient narrates how he could not go upstairs and play basketball. After treatment, his life changed drastically, and he was able to run up and down the stairs, return to construction work, and is happy to recommend QC Kinetix (Doral) to the broader public.

To chat one-on-one with a regenerative medicine provider at QC Kinetix (Doral), call (305) 381-9000 or visit the clinic located at 730 NW 107th Ave, Suite 210, Miami, FL, 33172, United States. As a preferred regenerative medicine clinic, the facility in Doral has joined the growing list of QC Kinetix clinics.

Media Contact

Company NameQC Kinetix (Doral)Contact NameScott HootsPhone(305) 381-9000Address730 NW 107th Ave, Suite 210CityMiamiStateFLPostal Code33172CountryUnited StatesWebsitehttps://qckinetix.com/south-florida/miami/doral/

Read more from the original source:
The Amazing World of QC Kinetix (Doral) Regenerative Medicine in Doral, FL - Digital Journal

Intensities of protein expression of markers are shown on viSNE map as spectrum colored dots, with low in blue, high in red. (Image: Bachmaier, et al. ACS Nano)

Using a protein nanoparticle they designed, scientists at the University of Illinois Chicago have identified two distinct subtypes of neutrophils and found that one of the subtypes can be used as a drug target for inflammatory diseases.

Neutrophils are a type of white blood cell that help fight infection, clear dead cell debris, and heal tissue injury. But for people with health conditions caused by chronic inflammation, like arthritis or Crohns disease, or excessive inflammation, like sepsis, the role of neutrophils may be deleterious. Neutrophils have been described in research as also contributing to tissue damage the double-edged sword of inflammation. Unfortunately, current drugs for inflammatory diseases that target neutrophils suppress all their effects, including their anti-infection and healing functions.

The UIC team is the first to characterize neutrophils into two subsets.

Understanding the differences between these neutrophil subsets opens the door for more research on treatments that address inflammatory diseases without increasing patients risks of infections, said study author Kurt Bachmaier, assistant professor in the department of pharmacology and regenerative medicine at the College of Medicine, who led the research.

Bachmaier and his colleagues first used the nanoparticle platform, formulated from a protein called albumin, to analyze how neutrophils from bone marrow, blood, and spleen and lung tissues interact with the nanoparticle. They found that some neutrophils brought the albumin nanoparticle into the cell through a process called endocytosis, while others didnt.

The scientists labeled the subtype that readily endocytosed the nanoparticle as ANP-high, for albumin nanoparticle high. The neutrophils that did not absorb the albumin nanoparticle were labeled as ANP-low.

Further investigation with the albumin nanoparticle showed that the subtypes have different cell surface receptors and that they are functionally distinct in their helpful capacities to kill bacteria and their harmful potential to promote inflammation. ANP-highneutrophils did not help to kill bacteria but produced inordinate amounts of reactive oxygen species and inflammatory chemokines and cytokines, which contribute to inflammatory disease.

Because the ANP-high neutrophils are also the ones that captured the nanoparticle, the scientists conducted clever experiments using the albumin nanoparticle to deliver drug treatments. They filled the nanoparticle with an anti-inflammatory drug and administered it to mice with sepsis. They found that the mice treated with the drug-loaded nanoparticle had reduced signs of tissue inflammation, but that the neutrophilic host-defense was preserved.

The albumin nanoparticle, which was filled with the drug, specifically bound to ANP-high neutrophils and unloaded their cargo into the cell, stopping it in its tracks, Bachmaier said.We found ANP-high neutrophils not only in mice but also in humans, opening the possibility of neutrophil subset-specific targeted therapy for human inflammatory diseases.

Science can be a bit like magic by targeting only the ANP-high neutrophils, we stopped the out-of-control inflammation while preserving the bacteria-fighting inflammation of these Janus-like cells, said senior author Asrar Malik, Schweppe Family Distinguished Professor and head of the department of pharmacology and regenerative medicine.

These findings are reported in the article Albumin Nanoparticle Endocytosing Subset of Neutrophils for Precision Therapeutic Targeting of Inflammatory Tissue Injury, which is published in ACS Nano, a scientific publication of the American Chemical Society and the primary nanotechnology journal.

Co-authors of the article are Andrew Stuart, Amitabha Mukhopadhyay, Sreeparna Chakraborty, Zhigang Hong, Li Wang, Yoshikazu Tsukasaki, Mark Maienschein-Cline, Balaji Ganesh, Prasad Kanteti and Jalees Rehman.

Here is the original post:
Newly identified neutrophil subset is a promising therapeutic target | UIC Today - UIC Today

Pune, April 04, 2022 (GLOBE NEWSWIRE) -- Stem cells refer to the undifferentiated biological cells that differentiate into specialized cells and divide to produce more stem cells. They are found in multicellular organisms and are of two types mainly embryonic stem cells and adult stem cells. These cells are present in areas in the body such as bone marrow, adipose tissue, and blood. Stem cells are also taken from umbilical cord blood. The stem cell population in the body is maintained through two processes, which include obligatory asymmetric replication and stochastic differentiation. Stem cells play an important role in the natural healing process of the body and introduction of stem cells has shown positive results in the treatment of many diseases such as cancer. The significance of stem cell assays lies in the fact that they are used for various processes such as viability or cytotoxicity studying, isolation and purification of stem cells, cell identification, cell proliferation, and cell differentiation for research purposes. In the case of stem cell transplant, initially, the embryonic stem cells are specialized into necessary adult cell type. Then, these cells are used to replace the tissue that is damaged due to any disease or injury.

The growth of thestem cell assays market corresponds with that of the biotechnology and biopharmaceutical industries, as these form significant end users for stem cell research products. The continuation of this trend the growth of the end-user base has compelled a number of companies to launch new products and invest in stem cell-based therapies. The growing incidence of cancer is increasing across the globe due to the rise in the aging population and changing lifestyle habits. This in turn, is accelerating the demand for anticancer drugs and therapies globally. The growing prevalence of various diseases such as cancer and cardiovascular diseases and the potential of stem cell therapy in the management of these diseases is projected to boost the growth of the Stem Cell Assay Market. Stem cell transplant replaces the neurons damaged by spinal cord injury, Alzheimers disease, and stroke. These factors are expected to drive the growth of the Stem Cell Assay Market.

Get a Sample Copy of the Report https://www.marketdatacentre.com/sample/8

The development in embryonic & adult stem cell assay will be beneficial to the global market. The increasing adoption of stem cell therapies has significantly helped the market to grow substantially. The continuously increasing healthcare expenditure and funding by several governments and private players in the field of stem cell research have boosted the market. Moreover, technological advancement in the instruments has driven the demand for stem cell assays in the market.Emergence of microfluidics in stem cell research, high growth potential of single stem cell analysis sequencing, and untapped potential in emerging markets offer favourable growth opportunities.

The Global Stem Cell Assay Market is segmented on the basis of Product, Cell types, Application, Assay, and region. Based on product market is segmented into Instruments, Reagents and kits. The instruments segment accounted for the largest share of global Stem Cell Assay Market. Some of the major factors driving the growth of this segment include ongoing technological innovations in stem cell instruments and the rising number of stem cell research activities.

Based on cell types market is divided into Adult Stem Cells (Induced Pluripotent Stem Cells, Mesenchymal Stem Cells, Neural Stem Cells, Hematopoietic Stem Cells, and Umbilical Cord Stem Cells) and Human Embryonic Stem Cells. By application, the market is segmented into regenerative medicine and therapy development, drug discovery and development, and clinical research. The regenerative medicine and therapy development segment accounted for the largest share of the global Stem Cell Assay market. The increasing demand for stem cells in the development of various types of cell therapies and growing regenerative medicine industry across the world are factors driving this market segment.

Based on Assay, The market is segmented into Cell Identification Assays, Viability Assays, Apoptosis Assays, Isolation & Purification Assays, and Others. The viability segment holds the largest market share during the forecast period. The factors that can be attributed to the widespread use of viability assays in stem cell research activities. Based, on the end user the market is divided into Government research institutes, Private Research Institutes and Industry Research.

Regional Analysis

Stem cell assay market is regionally segmented into North America, Asia-Pacific, Europe, and Rest of the World. North America followed by Europe had the biggest market for Stem cell based assays. In North America the large share of the geographical segment is attributed to factors such as the increasing incidence of chronic diseases and improved life sciences, research infrastructure and increasing funds for R&D in that region.

The European market is not far behind North America and is projected to show promising growth in the upcoming period. Factors such as increasing consciousness regarding cell based assays and increased adoption of R&D activities is propelling the markets growth rate.

Asia-Pacific market is expected to grow in the upcoming years. Growth in Asia-Pacific is due to rising infrastructural developments, growing funds in R&D by various public and private organizations is enhancing the market. The growing no. of Cancer cases, rising toxicity for examination and drug identification are escalating the stem cell assays market.

Speak to Our Research Analyst https://www.marketdatacentre.com/analyst/8

COMPANY PROFILES (Business Overview, Products/Services Offered, Financial Performance, R&D Intensity, Marketing & Sales Intensity, Recent Developments, Analyst Corner)*

At MDC Research, we offer research solutions to help businesses break the barriers of doubt or uncertainties when they plan to expand their growth. Our researchers compile data and information that help chief executive officers decide which growth opportunities in a market to pursue.

MDC Research is known for conducting well-researched reports, and the expertise of our researchers contributes to the outstanding quality of our reports. MDC Research enables businesses to make impactful decisions by blending innovation and analytical thinking. Our unique blend of these two skills assures you access to the most complete and up-to-date information about your industry.

MDC Research has a wealth of experience using the latest methodologies to develop reports for a wide range of clients in diverse markets. Our commitment to delivering high-quality research and creating innovative reports is one of the reasons why MDC Research is such a trusted name in the business world today.

Buy the Premium Report https://www.marketdatacentre.com/checkout/8

Recent Developments

GE Healthcare inaugurated a new testing centre to enhance its research and manufacturing capabilities.

Danaher Company launched ClearLLAb 10C systems for flow cytometry labs.

PerkinElmer completed acquisition of Cisbio Bioassays.

Read Overview of the Report https://www.marketdatacentre.com/stem-cell-assay-market-8

About MDC:

Market Data Centre (Subsidiary of Yellow Bricks Global Services Private Limited)

Market Data Centre offers complete solutions for market research reports in miscellaneous businesses.These decisions making process depend on wider and systematic extremely important information created through extensive study as well as the most recent trends going on in the industry.The company also attempts to offer much better customer-friendly services and appropriate business information to achieve our clients ideas.

Read more:
Stem Cell Assay Market | Viability/Cytotoxicity Assay Segment Estimated to Account for the Largest Share - Here's Why - MDC Research - GlobeNewswire

Human ES cell derived RASC (respiratory airway secretory cell) transitioning to an Alveolar type 2 cell over time in culture

PHILADELPHIA A new type of cell that resides deep within human lungs and may play a key role in human lung diseases has been discovered by researchers at the Perelman School of Medicine at the University of Pennsylvania.

The researchers, who report their findings today in Nature, analyzed human lung tissue to identify the new cells, which they call respiratory airway secretory cells (RASCs). The cells line tiny airway branches, deep in the lungs, near the alveoli structures where oxygen is exchanged for carbon dioxide. The scientists showed that RASCs have stem-cell-like properties enabling them to regenerate other cells that are essential for the normal functioning of alveoli. They also found evidence that cigarette smoking and the common smoking-related ailment called chronic obstructive pulmonary disease (COPD) can disrupt the regenerative functions of RASCshinting that correcting this disruption could be a good way to treat COPD.

COPD is a devastating and common disease, yet we really dont understand the cellular biology of why or how some patients develop it. Identifying new cell types, in particular new progenitor cells, that are injured in COPD could really accelerate the development of new treatments, said study first author Maria Basil, MD, PhD, an instructor of Pulmonary Medicine.

COPD typically features progressive damage to and loss of alveoli, exacerbated by chronic inflammation. It is estimated to affect approximately 10 percent of people in some parts of the United States and causes about 3 million deaths every year around the world. Patients often are prescribed steroid anti-inflammatory drugs and/or oxygen therapy, but these treatments can only slow the disease process rather than stop or reverse it. Progress in understanding COPD has been gradual in part because micethe standard lab animalhave lungs that lack key features of human lungs.

In the new study, Morrisey and his team uncovered evidence of RASCs while examining gene-activity signatures of lung cells sampled from healthy human donors. They soon recognized that RASCs, which dont exist in mouse lungs, are secretory cells that reside near alveoli and produce proteins needed for the fluid lining of the airway.

With studies like this were starting to get a sense, at the cell-biology level, of what is really happening in this very prevalent disease, said senior author Edward Morrisey, PhD, the Robinette Foundation Professor of Medicine, a professor of Cell and Developmental Biology, and director of the Penn-CHOP Lung Biology Institute at Penn Medicine.

Observations of gene-activity similarities between RASCs and an important progenitor cell in alveoli called AT2 cells led the team to a further discovery: RASCs, in addition to their secretory function, serve as predecessors for AT2 cellsregenerating them to maintain the AT2 population and keep alveoli healthy.

AT2 cells are known to become abnormal in COPD and other lung diseases, and the researchers found evidence that defects in RASCs might be an upstream cause of those abnormalities. In lung tissue from people with COPD, as well as from people without COPD who have a history of smoking, they observed many AT2 cells that were altered in a way that hinted at a faulty RASC-to-AT2 transformation.

More research is needed, Morrisey said, but the findings point to the possibility of future COPD treatments that work by restoring the normal RASC-to-AT2 differentiation processor even by replenishing the normal RASC population in damaged lungs.

The research was supported by the National Institutes of Health (HL148857, HL087825, HL134745, HL132999, 5T32HL007586-35, 5R03HL135227-02, K23 HL121406, K08 HL150226, DK047967, HL152960, R35HL135816, P30DK072482, U01HL152978), the BREATH Consortium/Longfunds of the Netherlands, the Parker B. Francis Foundation, and GlaxoSmithKline.

Penn Medicineis one of the worlds leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of theRaymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nations first medical school) and theUniversity of Pennsylvania Health System, which together form a $9.9 billion enterprise.

The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according toU.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $546 million awarded in the 2021 fiscal year.

The University of Pennsylvania Health Systems patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Centerwhich are recognized as one of the nations top Honor Roll hospitals byU.S. News & World ReportChester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nations first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.

Penn Medicine is powered by a talented and dedicated workforce of more than 52,000 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2021, Penn Medicine provided more than $619 million to benefit our community.

See original here:
Penn Researchers Discover New Cell Type in Human Lung with Regenerative Properties - Penn Medicine

CANTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis, a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that the latest advanced wound care research on its PuraPly AM, Affinity, Apligraf, NuShield, Novachor and Organogenesis Physician Solutions product lines will be showcased at the 2022 Symposium on Advanced Wound Care (SAWC) Spring Conference held April 6-10, 2022 in Phoenix, Arizona.

As a leading sponsor of this years conference, we are excited to share new research on our innovative product portfolio and hear from other thought leaders about advances in wound care, said Katie Mowry, Assistant Vice President, Research and Development for Organogenesis.

Attendees of this year's event are encouraged to visit the Organogenesis-supported breakfast symposium, "Investigating the Reliability and Transferability of Current RCT Based on Real-World Evidence" held Thursday, April 7, 2022 from 7:30 to 9:00 a.m. MST in room 224 at the Phoenix Convention Center. This panel discussion features Vickie R. Driver, DPM, MS, FACFAS FAAWC, Robert S. Kirsner, MD, PhD, FAAD, William Marston, MD, and Oscar M. Alvarez, PhD, CCT, FAPWCA, and will discuss how randomized controlled trials (RTCs) based on real-world evidence translates to evaluating wound care therapies.

The Organogenesis-sponsored Innovation Theatre lunch, Practical Utilization of Skin Substitutes for Chronic Wounds Using Prognostic Patient Indicators will be held Thursday, April 7, 2022 from 12:00 to 1:30 p.m. MST in room 224. This lunch will feature a presentation by Andrew J. Rader, DPM, FAENS, FACFAOM, FAPWCA, FACCWS of Memorial Hospital Wound Care and Nicholas Todd, DPM, FACFAS of Palo Alto Medical Foundation, who will discuss the use of prognostic patient indicators to determine the appropriate course of action for treating chronic wounds.

Attendees are encouraged to visit the Organogenesis exhibit hall booth (#703) to learn more about the latest advanced wound care products and latest studies. Organogenesis tissue regeneration specialists will be available to discuss the full portfolio of Organogenesis solutions that address wounds from head to toe.

The booth will be open during the following hours:

POSTER PRESENTATIONS OF INTEREST INCLUDE:

A Single Center Pilot Study Investigating the Effects of a Native Cross-Linked Extra Cellular Matrix with PHMB Antimicrobial Barrier to Manage Chronic Lower Extremity Wounds Exhibiting Bacterial Contamination as Determined by a Novel Violet-Light Imaging SystemWindy Cole, DPM, CWSP1, Janina Krumbeck, PhD

An Alternative Approach to the Management of Wounds Secondary to Diagnosis or Treatment of Skin CancersDaniel Kapp, MD, Laura Pfendler, PT, DPT, CWS

Real World Data Analyses of a Bilayered Living Cellular Construct and a Cryopreserved Placental Membrane for Use in Pressure InjuriesOscar M. Alvarez, PhD, Michael L. Sabolinski, MD

Real World Data Analyses of a Bilayered Living Cellular Construct and a Cryopreserved Cadaveric Skin Allograft for Use in Pressure InjuriesOscar M. Alvarez, PhD, Michael L. Sabolinski, MD

ABSTRACTS OF INTEREST INCLUDE:

Characterization of a Micronized Native Collagen Wound Matrix And Its Effectiveness In a Swine Full-Thickness Wound Healing Model Justin T. Avery, Vivek P. Raut, and Katie C. Mowry

Hypothermic Storage of Amnion and Chorion Membranes Retain Native Tissue CharacteristicsKatrina A. Harmon Ph.D.1 and Katie C. Mowry Ph.D.1

Robust Durability and Resistance to Degradation of a Native Type I Collagen Matrix with PHMB in vitroKatrina A. Harmon, Ph.D.1 and Katie C. Mowry Ph.D.1

About Organogenesis Holdings Inc.Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts for future events. Forward-looking statements may be identified by the use of words such as "will," "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," "extend," "continue" and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. Important factors that could cause actual outcomes to differ materially from those indicated by these forward-looking statements include risks and uncertainties described in the Companys Annual Report on Form 10-K for the year ended December 31, 2021. Organogenesis cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only to the date of this release, and Organogenesis undertakes no obligations to update or revise these statements, except as may be required by law.

Continued here:
Organogenesis Showcases Latest Advanced Wound Care Innovations and Research at SAWC Spring 2022 Conference - GlobeNewswire

DUBAI, United Arab Emirates, The global 3D cell culture market stands at a net worth of US$ 1.15 Bn in 2022, and is predicted to surge ahead at a CAGR of 9.8% over the forecast period to attain a valuation of US$ 2.67 Bn by 2031.

3D cell culture is a suitable alternative in translational and regenerative medicine since its represents a new, advanced, and robust platform for the investigation of complex biological procedures. 3D cell culture is projected to extend to various sectors of scientific research.

Request a report sample to gain comprehensive insights at https://www.futuremarketinsights.com/reports/sample/rep-gb-2843

The 3D cell culture market revenues surpassed US$ 778 million in 2018, as per a new FMI study. The market is estimated to grow at 7.8% y-o-y in 2019; key factors responsible for the projected market growth include,

While 2D cell culture revolutionized the research efforts in stem cells, tissue engineering, and molecular biology, 3D cell culture has pushed the boundaries of traditional 2D cell culture technique with functional superiority. As the R&D efforts continue to rise in a bid to investigate the cause of different diseases and improve human health, 3D cell culture is set to remain a highly sought-after technique in the coming years, says FMI.

The FMI study finds that scaffold-based 3D cell culture techniques are highly preferred over scaffold-free 3D cell culture. Owing to the significant adoption of scaffold-based 3D cell culture, the study finds that this technique garnered over 81% of the global market revenues.

Scaffold-based 3D cell culture techniques deliver researchers with additional functional operations in terms of material natural or synthetic and different mechanical properties.

The technique uses either hydrogel-based support or polymeric hard material based support. Both types of supports find equivalent penetration in terms of application, however revenues garnered from polymeric hard material based support are higher.

According to the study, revenues of polymeric hard material based support held over half the scaffold-based 3D cell culture technique revenues in 2018 and the trend is expected to continue in the future.

For any Queries Related with the Report, Ask an Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-2843

Application of 3D Cell Culture in Cancer Research Prominent

The FMI study estimates that 3D cell culture application in cancer research accounted for over 31% of the 3D cell culture market revenues in 2018. Cell culture is an integral part of cancer drug discovery practices. Greater strides are underway in the field to precisely characterize the diseases and develop advanced tumor cell lines using 3D cell culture techniques.

2D culture lines are considered as a standard for in vitro pre-clinical cancer treatment screening. However, more recently, the field is turning to 3D cell culture techniques to implement an ideal experimental model that mimics the human body environment to its best.

Stem cell technology is another lucrative field for 3D cell culture market. According to the FMI study, application in stem cell technology accounted for over one-fourth of the 3D cell culture market revenues in 2018. While 2D cell culture posed challenges of scalability in stem cell technology, apart from a few challenges, 3D cell culture has provided greater density and multi-fold expansion of the culture system in stem cell technology. Other fields that utilize 3D cell culture techniques are tissue regeneration, regenerative medicine, and drug discovery.

We Offer tailor-made Solutions to fit Your Requirements, Request Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-2843

Biotechnology and Pharmaceutical Industries - Prominent End-Users

The study reveals that the biotechnology and pharmaceutical industries were accounted for over one-fifth of the global 3D cell culture market revenues in 2018. Buoyancy in the biotechnology and pharmaceutical industries can be profitable for the 3D cell culture market in the coming years and over 9% growth is projected in 2019 over 2019.

Academic research institutes are the second prominent end-users of 3D cell cultures wherein they accounted for over one-fourth of the global 3d cell culture revenues in 2018. Government funding in cancer research projects carried out at academic institutes and organizations has increased significantly, thereby supporting the investments in advanced technologies including 3D cell culture techniques.

Explore FMIs Extensive ongoing Coverage on Healthcare Domain

Pure Red Cell Aplasia Market - Pure red cell aplasia is a type of rare disorder related to the production of blood in the body. Spongy tissue between bone marrow fails to produce sufficient blood for the body leading to anaemic conditions.

Mantle Cell Lymphoma Market - Mantle cell lymphoma (MCL) is a blood cancer that is rare and occurs due to the too much growth of lymphocytes. Mantle cell lymphoma occurs as a result of the formation of tumors in the lymph nodes, which enters the blood and spreads to the spleen, bone marrow, liver and digestive tract.

Insect cell lines Market - Tissue culture is the in-vitro procedure for culturing tissues aseptically using growth medium. Insect cell culture is a special media used for production of vaccines, virus like particles and recombinant proteins.

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:

Future Market Insights,1602-6 Jumeirah Bay X2 Tower,Plot No: JLT-PH2-X2A,Jumeirah Lakes Towers, Dubai,United Arab EmiratesFor Sales Enquiries: sales@futuremarketinsights.comWebsite: https://www.futuremarketinsights.com/Report: https://www.futuremarketinsights.com/reports/3d-cell-culture-market

Read the original post:
3D Cell Culture Market are Predicted to Increase at a Positive CAGR Of 9.8% from 2022 to 2031 - Comprehensive Research Report by FMI - BioSpace